Oddity Tech Ltd. (ODD)

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition

ODDITY Tech Ltd (ODD) Shares Fall 5.1% -- What GF Score of 71 Tells Investors

Earnings Estimates Moving Higher for Oddity Tech (ODD): Time to Buy?

Oddity Tech: Turnaround Potential And Discounted Debt Value Lever

Why Oddity Tech's Stock Skyrocketed 26.5% Today

Oddity Tech Ltd. (ODD) Q2 2026 Earnings Call Transcript

ODDITY shares surge on Q2 beat and raised FY26 guidance

ODDITY Tech Q2 Earnings Call Highlights

Oddity Tech (ODD) Beats Q2 Earnings and Revenue Estimates

ODDITY Tech Reports Second Quarter 2026 Results, Expects Sequential Revenue Improvement in the Third Quarter

Critical Comparison: ODDITY Tech (NASDAQ:ODD) versus Jamieson Wellness (OTCMKTS:JWLLF)

Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026

ODDITY Tech Ltd (ODD) Shares Surge 3.4% -- What GF Score of 77 Tells Investors

Empowered Funds LLC Takes Position in ODDITY Tech Ltd. $ODD

Amundi Grows Position in ODDITY Tech Ltd. $ODD

Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026